LENZ
LENZ Therapeutics, Inc.NASDAQHealthcare$9.67+3.42%ClosedMarket Cap: $303.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.06
P/S
15.88
EV/EBITDA
-3.14
DCF Value
$2.41
FCF Yield
-23.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.2%
Operating Margin
-477.5%
Net Margin
-430.3%
ROE
-37.5%
ROA
-26.8%
ROIC
-32.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.6M | 73.7% | $-38.5M | $-35.9M | $-1.16 | — |
| FY 2025 | $19.1M | 97.8% | $-91.1M | $-82.1M | $-2.85 | — |
| Q3 2025 | $12.5M | 99.0% | $-18.9M | $-16.7M | $-0.59 | — |
| Q2 2025 | $5.0M | 100.0% | $-16.9M | $-14.9M | $-0.53 | — |
| Q1 2025 | $0.00 | NaN% | $-16.9M | $-14.6M | $-0.53 | — |
| Q4 2024 | $0.00 | NaN% | $-15.2M | $-12.7M | $-0.46 | — |
| FY 2024 | $0.00 | -Infinity% | $-58.6M | $-49.8M | $-2.34 | $2.06 |
| Q3 2024 | $0.00 | NaN% | $-12.9M | $-10.2M | $-0.38 | — |
| Q2 2024 | $0.00 | NaN% | $-14.4M | $-10.3M | $-0.40 | — |
| Q1 2024 | $0.00 | NaN% | $-16.1M | $-16.6M | $-3.53 | $2.06 |
| Q4 2023 | $0.00 | NaN% | $-25.0M | $-23.7M | $-2.77 | — |
| FY 2023 | $0.00 | NaN% | $-72.4M | $-70.0M | $-15.30 | — |